News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ironwood Pharmaceuticals Begins Phase I Trial of Investigational IW-2143 Anxiety Drug in US


12/21/2012 8:44:58 AM

ADELAIDE, Australia, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) has been advised by its licensee Ironwood Pharmaceuticals Inc (Nasdaq:IRWD) that, following the submission of an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) last month, the planned Phase I clinical trial of the investigational anti-anxiety drug candidate IW-2143 (BNC210) has begun in the US.

Read at GlobeNewswire


comments powered by Disqus
   
Anxiety

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES